Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024)
Rapport Therapeutics (RAPP) posted quarterly Preferred Stock Liabilities of $145.3 million for Q1 2024, down 12.8% quarter-over-quarter from $166.6 million in Q4 2023.
Rapport Therapeutics (RAPP) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Preferred Stock Liabilities for 2 consecutive years, with $145.3 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Preferred Stock Liabilities changed N/A year-over-year to $145.3 million; the TTM figure through Mar 2024 stood at $145.3 million (changed N/A YoY), while the FY2023 annual figure was $166.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities fell to $145.3 million in Q1 2024 per RAPP's latest filing, from $166.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $166.6 million in Q4 2023 and bottomed at $89.5 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 145.25 Mn |
| Dec 31, 2023 | 166.58 Mn |
| Sep 30, 2023 | 89.49 Mn |
| Jun 30, 2023 | 89.49 Mn |